このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Beam Therapeutics 過去の業績
過去 基準チェック /06
Beam Therapeuticsの収益は年間平均-14.1%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 80.6%割合で 増加しています。
主要情報
-14.1%
収益成長率
45.6%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | 80.6% |
株主資本利益率 | -14.7% |
ネット・マージン | -37.3% |
前回の決算情報 | 31 Mar 2024 |
最近の業績更新
Recent updates
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25収支内訳
収支内訳
Beam Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
31 Mar 24 | 361 | -135 | 120 | 0 |
31 Dec 23 | 378 | -133 | 117 | 0 |
30 Sep 23 | 82 | -314 | 96 | 0 |
30 Jun 23 | 80 | -327 | 93 | 0 |
31 Mar 23 | 77 | -316 | 92 | -54 |
31 Dec 22 | 61 | -289 | 88 | 0 |
30 Sep 22 | 92 | -315 | 83 | 0 |
30 Jun 22 | 77 | -234 | 77 | 0 |
31 Mar 22 | 60 | -238 | 66 | 54 |
31 Dec 21 | 52 | -371 | 57 | 0 |
30 Sep 21 | 1 | -401 | 48 | 0 |
30 Jun 21 | 0 | -408 | 40 | 0 |
31 Mar 21 | 0 | -366 | 33 | 0 |
31 Dec 20 | 0 | -196 | 30 | 0 |
30 Sep 20 | 0 | -132 | 27 | 0 |
30 Jun 20 | 0 | -119 | 25 | 0 |
31 Mar 20 | 0 | -106 | 23 | 0 |
31 Dec 19 | 0 | -91 | 21 | 0 |
30 Sep 19 | 0 | -86 | 18 | 0 |
30 Jun 19 | 0 | -134 | 15 | 0 |
31 Mar 19 | 0 | -124 | 13 | 0 |
31 Dec 18 | 0 | -117 | 12 | 0 |
質の高い収益: BEAMは現在利益が出ていません。
利益率の向上: BEAMは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: BEAMは利益が出ておらず、過去 5 年間で損失は年間14.1%の割合で増加しています。
成長の加速: BEAMの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: BEAMは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。
株主資本利益率
高いROE: BEAMは現在利益が出ていないため、自己資本利益率 ( -14.75% ) はマイナスです。